134
Participants
Start Date
March 3, 2021
Primary Completion Date
December 15, 2026
Study Completion Date
January 30, 2027
RSC-1255 Dose Escalation
Phase 1a will enroll 30-40 participants to identify the dose limiting toxicity (DLT), recommended Phase 1b dose, and the safety and tolerability of RSC-1255. RSC-1255 is administered orally twice daily, without food. Each cycle is 21 days.
RSC-1255 Dose Expansion
Phase 1b will enroll 48-104 participants to further characterize the safety, pharmacology, and clinical efficacy of RSC-1255. RSC-1255 is administered orally twice daily, without food. Each cycle is 21 days.
RECRUITING
Sarah Cannon, SCRI Oncology Partners, Nashville
RECRUITING
Sarah Cannon, SCRI Oncology Partners - Health One, Denver
RECRUITING
University of California, Los Angles (UCLA) Department of Medicine - Hematology/Oncology, Los Angeles
RasCal Therapeutics, Inc.
INDUSTRY